2021
DOI: 10.1007/s11428-021-00755-7
|View full text |Cite
|
Sign up to set email alerts
|

Exenatid und Dapagliflozin zur Reduktion des Leberfetts bei Typ-2-Diabetes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 2 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?